99tcm labelled hl91 versus computed tomography and biopsy for the visualization of tumour recurrence of squamous head and neck carcinoma

Nuclear Medicine Communications

Volumn 22, Issue 3, 2001, Pages 269-275

  Van De Wiele, C ^a   Versijpt, J ^a   Dierckx, R A ^a   Moerman, M ^a   Lemmerling, M ^a   D'ASSELER Y ^a   Vermeersch, H ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

99Tcm; Biopsy; Computed tomography; HL91; Recurrence of head and neck carcinoma; Scintigraphy

Indexed keywords

DIAGNOSTIC AGENT; OXIME; RADIOPHARMACEUTICAL AGENT; TECHNETIUM COMPLEX; TECHNETIUM TC 99M 4,9 DIAZA 3,3,10,10 TETRAMETHYLDODECAN 2,11 DIONE DIOXIME; TECHNETIUM TC 99M 4,9-DIAZA-3,3,10,10-TETRAMETHYLDODECAN-2,11-DIONE DIOXIME; TECHNETIUM 99M;

ADULT; AGED; ARTICLE; BIOPSY; CLINICAL TRIAL; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HEAD AND NECK TUMOR; HUMAN; IMAGE PROCESSING; MALE; MIDDLE AGED; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PILOT STUDY; RADIOGRAPHY; REPRODUCIBILITY; SAFETY; SCINTISCANNING; SQUAMOUS CELL CARCINOMA; TUMOR RECURRENCE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; HEAD AND NECK CARCINOMA; ISOTOPE LABELING; OXIMETRY;

ADULT; AGED; BIOPSY; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOTECHNETIUM COMPOUNDS; OXIMES; PILOT PROJECTS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SAFETY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0034744684     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200103000-00002     Document Type: Review

References (26)

1. Archer MC, Edwards B, Powell NA. Radiopharmaceuticals for imaging hypoxia. In: Mather SJ, ed. Current directions in radiopharmaceutical research and development. The Netherlands: Kluwer, 1996: 81-88.
2. Gatenby RA, Kessler HB, Rosenblum SJ, et al. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiotherapy. Int J Radiat Oncol Biol Phys 1988; 14: 831-838.
3. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997; 38: 285-289.
4. Stadler P, Becker A, Feldmann HJ, Dunst J, Wurschmidt F, Molls M. Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int J Radiat Oncol Biol Phys 1999; 44: 749-754.
5. Overgaard J, Hansen HS, Overgaard M, et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 1998; 46: 135-146.
6. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996; 41: 31-39.
7. Chapman JD. Measurement of tumor hypoxia by invasive and non-invasive procedures: a review of recent clinical studies. Radiother Oncol 1991; 20: 13-19.
8. Chapman JD, Coia LR, Stobbe CC, Engelhardt EL, Fenning MC, Schneider RF. Prediction of tumour hypoxia and radioresistance with nuclear medicine markers. Br J Cancer 1996; 74: S204-S208.
9. Koole M, D’Asseler Y, Van Laere K, et al. MRI-SPET and SPET-SPET brain coregistration: Evaluation of eight different algorithms. Nucl Med Commun 1999; 20: 659-669.
10. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OCA. Concentration of oxygen dissolved in tissues at time of irradiation as a factor of radiotherapy. Br J Radiol 1953; 26: 638-648.
11. Olive PL, Durand RE. Misonidazole binding in SCC tumors in relation to the tumor blood supply. Int J Radiat Oncol Biol Phys 1989; 16: 755-761.
12. Overgaard J, Sand Hansen H, Anderson AP, et al. Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of the larynx and pharynx: report from the DAHANCA 2 study. Int J Radiat Oncol Biol Phys 1989; 16: 1063-1068.
13. Koh WJ, Rasey JS, Evans ML, et al. Imaging of hypoxia in human tumors with F-18 fluoromisonidazole. Int J Radiat Oncol Biol Phys 1991; 22: 199-212.
14. Koh J, Bergman KS, Rasey JS, et al. Evaluation of oxygen status during fractionated radiotherapy in human non-small cell lung cancers using F-18 fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys 1995; 33: 391-398.
15. Jette DC, Wiebe LI, Flanagan RJ, Lee J, Chapman JD. Iodoazomycin riboside (1-5′-iodo-5′-deoxyribofuranosyl-2-nitroimidazole), a hypoxic cell marker. Radiat Res 1986; 105: 169-179.
16. Mannan RH, Somayaji VV, Lee J, Mercer JR, Chapman JD, Wiebe LI. Radioiodinated (1-5′-iodo-5′-deoxy-(d-ribofuranosyl)-2-nitorimadazole (iodoazomycin arabinoside: IAZA): a novel marker of tissue hypoxia. J Nucl Med 1991; 32: 1764-1770.
17. Parliament MB, Chapman JD, Urtasun RC, et al. Non-invasive assessment of human tumor hypoxia with 123I-iodoazomycin arabinoside: preliminary report of a clinical study. Br J Cancer 1992; 65: 90-95.
18. Urtasun RC, Chapman JD, Raleigh JA, Franko AJ, Koch JC. Binding of 3H-misonidazole to solid human tumors as a measure of tumor hypoxia. Int J Radiat Oncol Biol Phys 1986; 12: 1263-1267.
19. Terris DJ, Dunphy EP. Oxygen tension measurements of head and neck cancers. Arch Otolaryngol Head Neck Surg 1994; 120: 283-287.
20. Gabalski EC, Adam M, Pinto H, Brown JM, Bloch DA, Terris DJ. Pretreatment and midtreatment measurement of oxygen tension levels in head and neck cancers. Laryngoscope 1998; 108: 1856-1860.
21. Becker A, Hansgen G, Bloching M, Weigel C, Lautenschlager C, Dunst J. Oxygenation of squamous cell carcinoma of the head and neck: comparison of primary tumors, neck node metastases, and normal tissue. Int J Radiat Oncol Biol Phys 1998; 42: 35-41.
22. Lartigau E, Luschini A, Weeger P, et al. Variations in tumour oxygen tension (pO2) during accelerated radiotherapy of head and neck carcinoma. Eur J Cancer 1998; 34: 856-861.
23. Groshar D, McEwan AJB, Parliament MB, et al. Imaging tumor hypoxia and tumor perfusion. J Nucl Med 1993; 34: 885-888.
24. Chapman JD, Urtasun RC, Franko AJ, Raleigh JA, Meeker BE, McKinnon SA. The measurement of oxygenation status of individual tumors. In: Fowler JF, Herbert DE, Kinsella TJ, Ortin CG, eds. Prediction of response in radiation therapy: The physical and biological basis. New York: American Institute of Physics, 1989: 49-60.
25. Cook GJR, Houston S, Barrington SF, Fogelman I. Technetium-99m-labeled HL 91 to identify tumor hypoxia: correlation with fluorine-18-FDG. J Nucl Med 1998; 39: 99-103.
26. Urtasun RC, Parliament MB, McEwan AJ, et al. Measurement of hypoxia in human tumours by non-invasive spect imaging of iodazomycin arabinoside. Br J Cancer 1996; 74: S209-S212.